Hikma Pharmaceuticals (LON:HIK) Trading Down 0.1% – Here’s Why

Shares of Hikma Pharmaceuticals PLC (LON:HIK) were down 0.1% during trading on Thursday . The company traded as low as GBX 1,614 and last traded at GBX 1,652. Approximately 833,808 shares changed hands during mid-day trading, a decline of 88% from the average daily volume of 6,893,593 shares. The stock had previously closed at GBX 1,653.

Analyst Upgrades and Downgrades

HIK has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft cut their price target on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set a “buy” rating on the stock in a report on Friday, January 9th. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,360 target price on shares of Hikma Pharmaceuticals in a research report on Friday, November 7th. Berenberg Bank reiterated a “buy” rating and issued a GBX 2,300 target price on shares of Hikma Pharmaceuticals in a research note on Thursday, January 22nd. Peel Hunt reissued a “buy” rating and set a GBX 2,170 price target on shares of Hikma Pharmaceuticals in a report on Friday, November 7th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating on the stock in a report on Friday, November 7th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of GBX 2,326.

Hikma Pharmaceuticals Trading Down 15.5%

The business’s 50 day moving average price is GBX 1,560.84 and its two-hundred day moving average price is GBX 1,647.04. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66. The company has a market capitalization of £3.09 billion, a price-to-earnings ratio of 8.36, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 800+ (as of Feb 2025) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.